Vaxcyte Inc.
06/23/2026 | Press release | Distributed by Public on 06/23/2026 14:09
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 17, 2026, Jacks Lee notified the Board of Directors (the "Board") of Vaxcyte, Inc. ("the "Company") of his retirement from the Board, effective as of June 17, 2026. Mr. Lee's retirement was not the result of any disagreement or dispute with the Company. The Company thanks Mr. Lee for his considerable contributions over the course of his Board service. Effective upon his retirement, Mr. Lee entered into a consulting agreement with the Company pursuant to which he will serve as a consultant to the Company on matters relating to global strategic supply and manufacturing operations.
On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately. Dr. Slaoui's term will expire at the Company's annual meeting of stockholders in 2028.
The Board has determined that Dr. Slaoui qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards. There are no arrangements or understandings between Dr. Slaoui and any other persons pursuant to which he was selected as a director. Additionally, there are no transactions involving the Company and Dr. Slaoui that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.
Dr. Slaoui will receive compensation in accordance with the Company's non-employee director compensation program as in effect from time to time (the "Director Compensation Program"), as most recently described under the section titled "Non-Employee Director Compensation" in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2026; provided, however, that the equivalent value of the annual equity grant for all directors is currently set at $430,000.
The Company has entered into its standard form of indemnification agreement with Dr. Slaoui.
Vaxcyte Inc. published this content on June 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 23, 2026 at 20:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]